blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3307724

EP3307724 - (Z)-2-(1H-INDOL-3-YL)-3-(ISOQUINOLIN-5-YL)ACRYLONITRILE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOSOME INHIBITORY AND ANTI-MITOTIC ACTIVITY FOR TREATING HYPERPROLIFERATIVE DISEASES [Right-click to bookmark this link]
Former [2018/16]SELECTIVE ANTI-CANCER COMPOUNDS
[2020/07]
StatusNo opposition filed within time limit
Status updated on  16.04.2021
Database last updated on 24.07.2024
FormerThe patent has been granted
Status updated on  08.05.2020
FormerGrant of patent is intended
Status updated on  29.01.2020
FormerRequest for examination was made
Status updated on  22.03.2018
FormerThe international publication has been made
Status updated on  16.12.2016
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
National University of Singapore
21 Lower Kent Ridge Road
Singapore 119077 / SG
[2018/16]
Inventor(s)01 / LEE, Sang Hyun
Center for Technology and Development (Level 6)
Duke-NUS
8 College Road
Singapore 169857 / SG
02 / DYMOCK, Brian William
c/o National University of Singapore
Faculty of Science
Department of Pharmacy
21 Lower Kent Ridge Road
Singapore 119077 / SG
03 / KITAGAWA, Mayumi
c/o National University of Singapore
Duke-NUS Medical School
21 Lower Kent Ridge Road
Singapore 119077 / SG
04 / SEE, Cheng Shang
c/o National University of Singapore
Faculty of Science
Department of Pharmacy
21 Lower Kent Ridge Road
Singapore 119077 / SG
 [2018/31]
Former [2018/16]01 / LEE, Sang Hyun
c/o National University of Singapore
Duke-NUS Medical School
21 Lower Kent Ridge Road
Singapore 119077 / SG
02 / DYMOCK, Brian William
c/o National University of Singapore
Faculty of Science
Department of Pharmacy
21 Lower Kent Ridge Road
Singapore 119077 / SG
03 / KITAGAWA, Mayumi
c/o National University of Singapore
Duke-NUS Medical School
21 Lower Kent Ridge Road
Singapore 119077 / SG
04 / SEE, Cheng Shang
c/o National University of Singapore
Faculty of Science
Department of Pharmacy
21 Lower Kent Ridge Road
Singapore 119077 / SG
Representative(s)McNab, Donald C., et al
Marks & Clerk LLP
40 Torphichen Street
Edinburgh EH3 8JB / GB
[2020/24]
Former [2018/16]McNab, Donald C.
Marks & Clerk LLP
Atholl Exchange
6 Canning Street
Edinburgh EH3 8EG / GB
Application number, filing date16807930.910.06.2016
[2018/16]
WO2016SG50269
Priority number, dateSG20151004656U12.06.2015         Original published format: SG10201504656U
[2018/16]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016200339
Date:15.12.2016
Language:EN
[2016/50]
Type: A1 Application with search report 
No.:EP3307724
Date:18.04.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 15.12.2016 takes the place of the publication of the European patent application.
[2018/16]
Type: B1 Patent specification 
No.:EP3307724
Date:10.06.2020
Language:EN
[2020/24]
Search report(s)International search report - published on:AU15.12.2016
(Supplementary) European search report - dispatched on:EP11.02.2019
ClassificationIPC:C07D401/14, C07D405/14, C07D401/06, C07D401/12, C07D471/04, C07D495/14, C07D519/00, A61K31/4725, A61K31/4709, A61P39/00, A61P35/00
[2020/07]
CPC:
C07D401/06 (EP,US); A61K31/4709 (EP,US); A61K31/4725 (EP,US);
A61P35/00 (EP,US); A61P39/00 (EP,US); C07D401/12 (EP,US);
C07D401/14 (EP,US); C07D405/14 (EP,US); C07D471/04 (EP,US);
C07D495/14 (EP,US); C07D519/00 (EP,US) (-)
Former IPC [2018/16]C07D401/06, C07D401/12, C07D401/14, C07D519/00, C07D471/04, C07D495/14, C07D405/14
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/16]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:(Z)-2-(1H-INDOL-3-YL)-3-(ISOQUINOLIN-5-YL)ACRYLONITRIL-DERIVATE UND ÄHNLICHE VERBINDUNGEN MIT LYSOSOMHEMMENDER UND ANTI-MITOTISCHER WIRKUNG ZUR BEHANDLUNG VON HYPERPROLIFERATIVEN ERKRANKUNGEN[2020/07]
English:(Z)-2-(1H-INDOL-3-YL)-3-(ISOQUINOLIN-5-YL)ACRYLONITRILE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOSOME INHIBITORY AND ANTI-MITOTIC ACTIVITY FOR TREATING HYPERPROLIFERATIVE DISEASES[2020/07]
French:DÉRIVÉS DE (Z)-2-(1H-INDOL-3-YL)-3-(ISOQUINOLIN-5-YL)ACRYLONITRILE ET COMPOSÉS SIMILAIRES AVEC ACTIVITÉ INHIBITOIRE DE LYSOSOME ET ANTI-MITOTIQUE POUR TRAITER MALADIES HYPERPROLIFÉRATIVES[2020/07]
Former [2018/16]SELEKTIVE ANTIKREBSVERBINDUNGEN
Former [2018/16]SELECTIVE ANTI-CANCER COMPOUNDS
Former [2018/16]COMPOSÉS ANTI-CANCÉREUX SÉLECTIFS
Entry into regional phase11.01.2018National basic fee paid 
11.01.2018Search fee paid 
11.01.2018Designation fee(s) paid 
11.01.2018Examination fee paid 
Examination procedure11.01.2018Examination requested  [2018/16]
11.01.2018Date on which the examining division has become responsible
06.09.2019Amendment by applicant (claims and/or description)
30.01.2020Communication of intention to grant the patent
27.04.2020Fee for grant paid
27.04.2020Fee for publishing/printing paid
27.04.2020Receipt of the translation of the claim(s)
Opposition(s)11.03.2021No opposition filed within time limit [2021/20]
Fees paidRenewal fee
25.06.2018Renewal fee patent year 03
13.06.2019Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU10.06.2016
AL10.06.2020
AT10.06.2020
CY10.06.2020
CZ10.06.2020
DK10.06.2020
EE10.06.2020
FI10.06.2020
HR10.06.2020
LT10.06.2020
LU10.06.2020
LV10.06.2020
MC10.06.2020
MK10.06.2020
MT10.06.2020
PL10.06.2020
RO10.06.2020
RS10.06.2020
SE10.06.2020
SI10.06.2020
SK10.06.2020
SM10.06.2020
TR10.06.2020
BG10.09.2020
NO10.09.2020
GR11.09.2020
IS10.10.2020
PT12.10.2020
[2022/32]
Former [2022/27]HU10.06.2016
AL10.06.2020
AT10.06.2020
CY10.06.2020
CZ10.06.2020
DK10.06.2020
EE10.06.2020
FI10.06.2020
HR10.06.2020
LT10.06.2020
LU10.06.2020
LV10.06.2020
MC10.06.2020
MT10.06.2020
PL10.06.2020
RO10.06.2020
RS10.06.2020
SE10.06.2020
SI10.06.2020
SK10.06.2020
SM10.06.2020
TR10.06.2020
BG10.09.2020
NO10.09.2020
GR11.09.2020
IS10.10.2020
PT12.10.2020
Former [2021/24]AL10.06.2020
AT10.06.2020
CZ10.06.2020
DK10.06.2020
EE10.06.2020
FI10.06.2020
HR10.06.2020
LT10.06.2020
LU10.06.2020
LV10.06.2020
MC10.06.2020
PL10.06.2020
RO10.06.2020
RS10.06.2020
SE10.06.2020
SI10.06.2020
SK10.06.2020
SM10.06.2020
BG10.09.2020
NO10.09.2020
GR11.09.2020
IS10.10.2020
PT12.10.2020
Former [2021/21]AL10.06.2020
AT10.06.2020
CZ10.06.2020
DK10.06.2020
EE10.06.2020
FI10.06.2020
HR10.06.2020
LT10.06.2020
LU10.06.2020
LV10.06.2020
MC10.06.2020
PL10.06.2020
RO10.06.2020
RS10.06.2020
SE10.06.2020
SK10.06.2020
SM10.06.2020
BG10.09.2020
NO10.09.2020
GR11.09.2020
IS10.10.2020
PT12.10.2020
Former [2021/18]AL10.06.2020
AT10.06.2020
CZ10.06.2020
EE10.06.2020
FI10.06.2020
HR10.06.2020
LT10.06.2020
LU10.06.2020
LV10.06.2020
MC10.06.2020
PL10.06.2020
RO10.06.2020
RS10.06.2020
SE10.06.2020
SK10.06.2020
SM10.06.2020
BG10.09.2020
NO10.09.2020
GR11.09.2020
IS10.10.2020
PT12.10.2020
Former [2021/15]AL10.06.2020
AT10.06.2020
CZ10.06.2020
EE10.06.2020
FI10.06.2020
HR10.06.2020
LT10.06.2020
LU10.06.2020
LV10.06.2020
PL10.06.2020
RO10.06.2020
RS10.06.2020
SE10.06.2020
SK10.06.2020
SM10.06.2020
BG10.09.2020
NO10.09.2020
GR11.09.2020
IS10.10.2020
PT12.10.2020
Former [2021/10]AL10.06.2020
AT10.06.2020
CZ10.06.2020
EE10.06.2020
FI10.06.2020
HR10.06.2020
LT10.06.2020
LV10.06.2020
PL10.06.2020
RO10.06.2020
RS10.06.2020
SE10.06.2020
SK10.06.2020
SM10.06.2020
BG10.09.2020
NO10.09.2020
GR11.09.2020
IS10.10.2020
PT12.10.2020
Former [2021/09]AL10.06.2020
AT10.06.2020
CZ10.06.2020
EE10.06.2020
FI10.06.2020
HR10.06.2020
LT10.06.2020
LV10.06.2020
RO10.06.2020
RS10.06.2020
SE10.06.2020
SM10.06.2020
BG10.09.2020
NO10.09.2020
GR11.09.2020
PT12.10.2020
Former [2021/04]AL10.06.2020
FI10.06.2020
HR10.06.2020
LT10.06.2020
LV10.06.2020
RS10.06.2020
SE10.06.2020
BG10.09.2020
NO10.09.2020
GR11.09.2020
Former [2021/01]FI10.06.2020
HR10.06.2020
LT10.06.2020
LV10.06.2020
RS10.06.2020
SE10.06.2020
BG10.09.2020
NO10.09.2020
GR11.09.2020
Former [2020/51]FI10.06.2020
HR10.06.2020
LT10.06.2020
LV10.06.2020
RS10.06.2020
SE10.06.2020
NO10.09.2020
GR11.09.2020
Former [2020/50]FI10.06.2020
HR10.06.2020
LT10.06.2020
LV10.06.2020
SE10.06.2020
NO10.09.2020
GR11.09.2020
Former [2020/48]FI10.06.2020
LT10.06.2020
SE10.06.2020
NO10.09.2020
Former [2020/47]LT10.06.2020
NO10.09.2020
Documents cited:Search   [ ] - No further relevant documents disclosed
International search[X]WO2004031158  (SANOFI SYNTHELABO [FR], et al) [X] 1-4, 6-8, 14-20 * page 62, compound 5; claims *;
 [X]WO2009073620  (NEWLINK GENETICS [US], et al) [X] 1-4, 6, 7, 14-20* page 49, compound 00888; abstract *;
 [X]  - "1H-Indazole-3- carboxamide, N-5-quinolinyl- ( CA INDEX NAME", Registry, (20100805), Database accession no. 1235327-94-2, URL: STN, XP055504577 [X] 1-4, 6-8, 15 * the compound *
 [X]  - "1H-Indole-3- carboxamide, N-(2-methyl-5-quinolinyl)- ( CA INDEX NAME", Registry, (20100805), Database accession no. 1235117-62-0, URL: STN, XP055504583 [X] 1-4, 6-8, 15 * the compound *
 [X]  - "1H-Indazole-3- carboxamide, N-(2-methyl-5-quinolinyl)- ( CA INDEX NAME", Registry, (20100804), Database accession no. 1234868-84-8, URL: STN, XP055504587 [X] 1-4, 6, 7, 15 * the compound *
 [X]  - "1H-Indole-3- carboxamide, N-5-quinolinyl- ( CA INDEX NAME", Registry, (20100719), Database accession no. 1232776-29-2, URL: STN, XP055504595 [X] 1-4, 6-8, 15 * the compound *
by applicantWO2004031158
 WO2009073620
    - GORDON DJRESIO BPELLMAN D., Nat Rev Genet., (20120000), vol. 13, no. 3, pages 189 - 203
    - JORDAN, M.A.WILSON, L., Nat Rev Cancer, (20040000), vol. 4, pages 253 - 265
    - MACINTOSH, R.L.RYAN, K.M., Seminars in Cancer Biology, (20130000), vol. 23, pages 344 - 351
    - TANG et al., Cell, (20110000), vol. 144, no. 4, pages 499 - 512
    - SIEGEL JJAMON A, Annu Rev Cell Dev Biol., (20120000), vol. 28, pages 189 - 214
    - BUNDEGAARD, H., Design of Prodrugs, Elsevier, (19850000), pages 1 - 92
    - LANGER, Science, (19900000), vol. 249, page 1527
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.